vs

Side-by-side financial comparison of Blend Labs, Inc. (BLND) and REGENXBIO Inc. (RGNX). Click either name above to swap in a different company.

Blend Labs, Inc. is the larger business by last-quarter revenue ($32.4M vs $30.3M, roughly 1.1× REGENXBIO Inc.). Blend Labs, Inc. runs the higher net margin — -7.8% vs -221.3%, a 213.5% gap on every dollar of revenue. On growth, REGENXBIO Inc. posted the faster year-over-year revenue change (43.0% vs 7.6%). Blend Labs, Inc. produced more free cash flow last quarter ($-21.0K vs $-52.8M). Over the past eight quarters, REGENXBIO Inc.'s revenue compounded faster (39.4% CAGR vs 16.6%).

GU Energy Labs is a company based in Berkeley, California, that produces sports nutrition products, most notably energy gels. Often consumed during endurance events, the gels are designed to be quickly and easily digested during any type of activity. Other products include energy chews, drink mixes, hydration tablets, stroopwafels and a Roctane line that includes an energy drink mix, protein recovery drink mix, gel, and capsules. The company was founded in 1994 by Bill Vaughan, who began crea...

REGENXBIO Inc. is a clinical-stage biotechnology firm focused on gene therapy for rare severe genetic diseases. It licenses its proprietary AAV vector technology to global biopharma partners, and advances its own pipeline targeting ophthalmology, metabolic and neurodegenerative disorders.

BLND vs RGNX — Head-to-Head

Bigger by revenue
BLND
BLND
1.1× larger
BLND
$32.4M
$30.3M
RGNX
Growing faster (revenue YoY)
RGNX
RGNX
+35.4% gap
RGNX
43.0%
7.6%
BLND
Higher net margin
BLND
BLND
213.5% more per $
BLND
-7.8%
-221.3%
RGNX
More free cash flow
BLND
BLND
$52.8M more FCF
BLND
$-21.0K
$-52.8M
RGNX
Faster 2-yr revenue CAGR
RGNX
RGNX
Annualised
RGNX
39.4%
16.6%
BLND

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BLND
BLND
RGNX
RGNX
Revenue
$32.4M
$30.3M
Net Profit
$-2.5M
$-67.1M
Gross Margin
75.7%
Operating Margin
-11.1%
-190.0%
Net Margin
-7.8%
-221.3%
Revenue YoY
7.6%
43.0%
Net Profit YoY
-207.0%
-31.2%
EPS (diluted)
$-1.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLND
BLND
RGNX
RGNX
Q4 25
$32.4M
$30.3M
Q3 25
$32.7M
$29.7M
Q2 25
$31.6M
$21.4M
Q1 25
$26.8M
$89.0M
Q4 24
$30.1M
$21.2M
Q3 24
$33.1M
$24.2M
Q2 24
$28.7M
$22.3M
Q1 24
$23.8M
$15.6M
Net Profit
BLND
BLND
RGNX
RGNX
Q4 25
$-2.5M
$-67.1M
Q3 25
$12.1M
$-61.9M
Q2 25
$-6.8M
$-70.9M
Q1 25
$-9.5M
$6.1M
Q4 24
$-825.0K
$-51.2M
Q3 24
$-2.4M
$-59.6M
Q2 24
$-19.4M
$-53.0M
Q1 24
$-20.7M
$-63.3M
Gross Margin
BLND
BLND
RGNX
RGNX
Q4 25
75.7%
Q3 25
74.3%
Q2 25
73.8%
Q1 25
70.8%
Q4 24
74.2%
70.2%
Q3 24
74.0%
48.8%
Q2 24
70.9%
52.5%
Q1 24
67.3%
72.6%
Operating Margin
BLND
BLND
RGNX
RGNX
Q4 25
-11.1%
-190.0%
Q3 25
-16.4%
-176.3%
Q2 25
-15.3%
-296.3%
Q1 25
-29.7%
13.6%
Q4 24
-10.9%
-242.1%
Q3 24
-34.1%
-256.6%
Q2 24
-45.5%
-251.3%
Q1 24
-89.0%
-408.8%
Net Margin
BLND
BLND
RGNX
RGNX
Q4 25
-7.8%
-221.3%
Q3 25
37.0%
-208.3%
Q2 25
-21.6%
-331.8%
Q1 25
-35.5%
6.8%
Q4 24
-2.7%
-241.3%
Q3 24
-7.4%
-246.3%
Q2 24
-67.6%
-237.7%
Q1 24
-86.7%
-405.4%
EPS (diluted)
BLND
BLND
RGNX
RGNX
Q4 25
$-1.30
Q3 25
$0.02
$-1.20
Q2 25
$-1.38
Q1 25
$0.12
Q4 24
$-0.03
$-0.99
Q3 24
$-0.03
$-1.17
Q2 24
$-0.09
$-1.05
Q1 24
$-0.09
$-1.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLND
BLND
RGNX
RGNX
Cash + ST InvestmentsLiquidity on hand
$68.3M
$230.1M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$-30.5M
$102.7M
Total Assets
$170.0M
$453.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLND
BLND
RGNX
RGNX
Q4 25
$68.3M
$230.1M
Q3 25
$77.3M
$274.2M
Q2 25
$88.3M
$323.3M
Q1 25
$104.8M
$267.9M
Q4 24
$94.2M
$234.7M
Q3 24
$112.3M
$255.5M
Q2 24
$108.9M
$290.4M
Q1 24
$121.1M
$338.7M
Total Debt
BLND
BLND
RGNX
RGNX
Q4 25
$0
Q3 25
$0
Q2 25
$0
Q1 25
$0
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$138.9M
Stockholders' Equity
BLND
BLND
RGNX
RGNX
Q4 25
$-30.5M
$102.7M
Q3 25
$-13.4M
$161.5M
Q2 25
$-23.1M
$213.7M
Q1 25
$-17.2M
$274.2M
Q4 24
$-56.4M
$259.7M
Q3 24
$-49.6M
$301.4M
Q2 24
$-45.5M
$348.3M
Q1 24
$-35.8M
$390.7M
Total Assets
BLND
BLND
RGNX
RGNX
Q4 25
$170.0M
$453.0M
Q3 25
$188.6M
$525.2M
Q2 25
$182.2M
$581.0M
Q1 25
$187.5M
$490.9M
Q4 24
$178.1M
$466.0M
Q3 24
$186.1M
$519.1M
Q2 24
$185.4M
$569.4M
Q1 24
$201.8M
$629.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLND
BLND
RGNX
RGNX
Operating Cash FlowLast quarter
$1.5M
$-52.3M
Free Cash FlowOCF − Capex
$-21.0K
$-52.8M
FCF MarginFCF / Revenue
-0.1%
-174.0%
Capex IntensityCapex / Revenue
4.8%
1.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-81.0K
$-126.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLND
BLND
RGNX
RGNX
Q4 25
$1.5M
$-52.3M
Q3 25
$-3.6M
$-56.0M
Q2 25
$-6.5M
$-49.3M
Q1 25
$20.1M
$33.6M
Q4 24
$-4.6M
$-31.6M
Q3 24
$2.1M
$-40.5M
Q2 24
$-6.7M
$-45.5M
Q1 24
$-3.9M
$-55.5M
Free Cash Flow
BLND
BLND
RGNX
RGNX
Q4 25
$-21.0K
$-52.8M
Q3 25
$-5.8M
$-56.5M
Q2 25
$-10.1M
$-49.7M
Q1 25
$15.8M
$32.6M
Q4 24
$-7.1M
$-32.7M
Q3 24
$-1.4M
$-40.9M
Q2 24
$-8.5M
$-46.0M
Q1 24
$-5.8M
$-56.0M
FCF Margin
BLND
BLND
RGNX
RGNX
Q4 25
-0.1%
-174.0%
Q3 25
-17.6%
-189.9%
Q2 25
-31.9%
-232.8%
Q1 25
58.9%
36.6%
Q4 24
-23.5%
-154.2%
Q3 24
-4.1%
-168.9%
Q2 24
-29.7%
-206.2%
Q1 24
-24.5%
-358.5%
Capex Intensity
BLND
BLND
RGNX
RGNX
Q4 25
4.8%
1.7%
Q3 25
6.5%
1.7%
Q2 25
11.4%
1.8%
Q1 25
16.1%
1.2%
Q4 24
8.3%
5.1%
Q3 24
10.4%
1.3%
Q2 24
6.5%
2.1%
Q1 24
8.2%
3.6%
Cash Conversion
BLND
BLND
RGNX
RGNX
Q4 25
Q3 25
-0.30×
Q2 25
Q1 25
5.53×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLND
BLND

Mortgage Suite$18.9M58%
Consumer Banking Suite$11.4M35%
Professional Services$2.1M6%

RGNX
RGNX

Novartis Gene Therapies$24.2M80%
Nippon Shinyaku Collaboration And License Agreement$4.3M14%
Nippon Shinyaku Services$1.4M5%

Related Comparisons